Orange Bank Africa Goes Live with Temenos SaaS
23.7.2020 16:00:00 EEST | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, today announced that Orange Bank Africa has gone live with cloud-native Temenos Transact delivered as SaaS. Temenos Transact core banking technology scales to support the bank to launch and drive financial inclusion in the African WAEMU region, starting with the Ivory Coast. Temenos’ cloud technology enables sustainable, long-term growth for Orange Bank Africa by reducing IT costs, operational complexity and delivering an improved cost/income ratio.
Temenos and its partner, MCB Consulting, worked closely with Orange Bank Africa to implement the solution remotely after the onset of the Covid-19 pandemic. Temenos’ core banking technology is hosted on Microsoft Azure. Temenos’ SaaS technology and dedicated team support resulted in a seamless implementation within the original project timescales despite the global emergency. Temenos’ Model Bank approach provided highly localized, pre-configured banking functionality so the new software could be deployed quickly, without the need for customization.
Banking services penetration in West Africa is relatively low compared to mobile phone penetration, leaving significant room for expansion of mobile financial services. According to recent research from the Economist Intelligence Unit, the affordability of smartphones is driving the development of mobile-only and mobile-first initiatives, like Orange Bank Africa – this was cited as the top innovation strategy by 37% of MEA-based bank executives.
Orange Bank Africa’s mobile-first banking strategy was developed to deliver financial services to consumers’ phones. Temenos’ technology will allow Orange Bank Africa to continuously innovate and provide customers with much-needed access to savings accounts and micro-loans. The new technology drives process automation for these services in order to deliver vital funding to more people at a faster rate and promote financial inclusion.
Patrick Roussel, Vice President, MEA Mobile Financial Services at Orange, commented: “Our mission is to deliver banking services to those that don’t yet have access with an offer that differentiates us from the competition: simple, accessible and above all mobile-first banking. In order for us to achieve this goal in West Africa, we needed a strategic technology partner with rich experience deploying banking software in the cloud. Temenos’ cutting-edge cloud technology, relentless focus on innovation and unrivalled regional experience makes it the perfect partner for Orange Bank Africa as we launch our operations. Temenos Transact gives us the scalability we need to grow and provide vital financial services to millions of customers.”
Jean-Michel Hilsenkopf, Chief Operating Officer, Temenos, said: “Across the globe, banks are moving to the cloud and achieving operational excellence that drives a higher banking performance. For Orange Bank Africa, the cloud is key for rapid market expansion and sustainable business growth. There is a growing need to provide people in West Africa with access to banking services and Orange Bank Africa will play a vital role in addressing this. Telcos like Orange are particularly well placed to offer differentiated banking services and enhanced customer experiences because of their established client base and mobile-centric capabilities. Temenos’ SaaS technology provides a powerful and flexible solution that will support Orange Bank Africa to continuously adapt to changes in the market and innovate quickly as customer demands evolve. We are excited to support the bank in delivering personalized mobile-banking services as they advance financial inclusion in West Africa.”
– Ends –
About Orange Bank Africa
Orange Bank Africa is a digital bank, the result of a partnership between two international groups, Orange and NSIA, both present in Africa for many years. Orange Bank Africa’s ambition is to provide as many people as possible with a micro-credit and savings solutions, directly from their mobile phone, and in complete security.
Orange Bank Africa is based in Abidjan, Ivory Coast, and is set to expand to Burkina Faso, Mali and Senegal.
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200723005528/en/
Contact information
Jessica Wolfe & Grace Collins
Temenos Global Public Relations
Tel: +1 610 232 2793 & + 44 20 7423 3969
Email : press@temenos.com
Alistair Kellie & Andrew Adie
Newgate Communications on behalf of Temenos
Tel: +44 20 7680 6550
Email: allnewgatetemenos@newgatecomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
